Among carriers of presenilin 1 (PSEN1), presenilin 2 (PSEN2), amyloid precursor protein (APP) mutations, or APP duplications with AD, as many as 47.7% experienced seizures during an 8.4-year follow-up period [13,21]. Here, PSEN2 is linked to Alzheimer disease.